Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin ®) injections in blepharospasm

Journal of Neural Transmission

Volumn 120, Issue 9, 2013, Pages 1345-1353

  Truong, Daniel D ^a   Gollomp, Stephen M ^b   Jankovic, Joseph ^c   Lewitt, Peter A ^d   Marx, Michael ^e   Hanschmann, Angelika ^e   Fernandez, Hubert H ^f  

^a Parkinson's and Movement Disorder Institute   (United States)

^b LANKENAU HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e MERZ PHARMACEUTICALS GMBH   (Germany)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Blepharospasm; Botulinum toxin; Dystonia; IncobotulinumtoxinA; Xeomin

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ANTIBODY PRODUCTION; ARTICLE; BLEPHAROSPASM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PTOSIS;

ADULT; AGED; ANTIBODIES, NEUTRALIZING; BLEPHAROSPASM; BOTULINUM TOXINS, TYPE A; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PATIENT SATISFACTION; SAFETY; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 84883464268     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-0998-9     Document Type: Article

References (24)

1. ® US Prescribing Information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/103000s5232lbl.pdf. Accessed 18 June 2012
2. Benecke R, Jost WH, Kañovský P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949-1951
3. ®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 308:103-109
4. Daly K (1997) Blepharospasm: an Australian survey. Int J Rehabil Res 20:41-50
5. Frevert J (2009) Xeomin is free from complexing proteins. Toxicon 54:697-701
6. ®. Drugs R D 10:67-73
7. Frevert J, Dressler D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 4:325-332
8. Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and non-neutralizing antibodies - therapeutic consequences. Exp Neurol 147:96-102
9. Hallett M, Evinger C, Jankovic J, Stacy M (2008) BEBRF International Workshop. Update on blepharospasm: report from the BEBRF International Workshop. Neurology 71:1275-1282
10. Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K, Nakajima H, Inoue K, Oguma K (1996) Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 64:1589-1594
11. Jankovic J, Orman J (1987) Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37:616-623
12. Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G (2009) Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord 24:407-413
13. Jankovic J, Comella C, Hanschmann A, Grafe S (2011) Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm - a randomized trial. Mov Disord 26:1521-1528
14. Kañovský P, Slawek J, Denes Z, Platz T, Sassin I, Comes G, Grafe S (2009) Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 32:259-265
15. Kañovský P, Slawek J, Denes Z, Platz T, Comes G, Grafe S, Pulte I (2011) Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med 43:486-492
16. Kenney C, Jankovic J (2008) Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 115:585-591
17. ® US Prescribing Information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 125360s007lbl.pdf. Accessed 19 June 2012
18. Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S (2006) Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303-312
19. Sesardic D, Jones RG, Leung T, Alsop T, Tierney R (2004) Detection of antibodies against botulinum toxins. Mov Disord 19(Suppl 8):S85-S91
20. Sethi KD, Rodriguez R, Olayinka B (2012) Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15:419-423
21. Truong D, Comella C, Fernandez HH, Ondo WG, Dysport Benign Essential Blepharospasm Study Group (2008) Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 14:407-414
22. Truong DD, Jost WH (2006) Botulinum toxin: clinical use. Parkinsonism Relat Disord 12:331-355
23. Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkämper P (2011) Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm 118:233-239
24. Wissel J, Müller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W (2000) Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 20:44-49